Commentary by the SEC’s Enforcement Director Identifies Areas of SEC Focus Applicable to the Pharmeceutical Industry

By | Life Sciences Legal Update | March 17, 2015
Commentary by the SEC’s Enforcement Director Identifies Areas of SEC Focus Applicable to the Pharmeceutical Industry

Recently, the United States Securities and Exchange Commission’s (“SEC”) Enforcement Director, Andrew Ceresney (“Ceresney”), spoke to pharmaceutical compliance personnel at the CBI’s Annual Pharmaceutical Compliance Congress and discussed three current areas of SEC focus most relevant to the pharmaceutical industry: the Foreign Corrupt Practices Act (“FCPA”), corporate disclosures relating to interactions with the Food and Drug Administration (“FDA”), and financial internal controls.